Sansure Biotech and Affiliated Parties to Acquire Equity Interests in Two Companies to Strengthen 'AI + Healthcare' Industrial Chain

March 15th eveningSansure Biotech(688289) disclosed an announcement, planning to jointly invest in two companies with the related party, Hunan Jinfurong Sansure Biotech Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as the "Fund").

Among them, Sansure Biotech Inc. plans to jointly invest with the fund to establish Hunan Sanvalley Bioscience Co., Ltd. (hereinafter referred to as "Sanvalley Bioscience"), which will serve as the investment entity for the subsequent acquisition of 100% equity in Huas Microbiology Technology (Shenzhen) Co., Ltd. (hereinafter referred to as "Huas Microbiology"). The listed company will contribute a total of 65.438 million yuan from its own funds, and the fund will invest 28.0449 million yuan. After the completion of this transaction, Sanvalley Bioscience and Huas Microbiology will be included in the company’s consolidated financial statements.

In addition, Sansure Biotech Inc. also plans to jointly invest in PHIL RIVERS TECHNOLOGY Co., Ltd. ("PHIL RIVERS") with the fund. Among them, the listed company will invest 40 million yuan of its own funds, and the fund will invest 50 million yuan. After the equity transfer and capital increase transactions, the listed company will hold 4.02% of PHIL RIVERS' equity, and the fund will hold 5.02% of PHIL RIVERS' equity.

It is disclosed that Wasun Micro is a company that develops, produces, and sells in vitro diagnostic reagents and supporting instruments for human and animal/pet use (detection targets include but are not limited to nucleic acids, proteins, small molecules, cells, etc.) based on its proprietary infrared fluorescence enhancement technology.

The company's existing products focus on immunofluorescence and have achieved more than 10 invention and utility model patents in areas such as the design of fluorescent dye molecules, the preparation of fluorescent nanobeads, supporting equipment and consumables for immunofluorescence/immunological diagnostics, and testing applications. The products have obtained over 20 NMPA registration certificates in China and more than 60 EU CE certifications, which can comprehensively cover the common and frequently occurring disease immunofluorescence testing needs within hospitals, as well as the continuous monitoring and management of various chronic diseases and early warning testing requirements in grassroots markets.

PHIL RIVERS TECHNOLOGY Co., Ltd. is a platform-based company that empowers pharmaceutical innovation through digital life technologies. Its core technology platform is built on a knowledge graph constructed from massive publicly available literature and biomedical research data. Based on this knowledge graph and PHIL RIVERS' AI platform, the company conducts in-depth exploration of disease biological mechanisms and possesses the capability to perform digital simulations (digital twins) for specific diseases or individual populations. It has obtained more than 10 core invention patents related to the aforementioned data mining and analysis methodologies.

Sansure Biotech believes that the capabilities of PHIL RIVERS are not only closely related to pharmaceutical development but also to the development of in vitro diagnostic products, representing a fundamental platform capability. Specifically, PHIL RIVERS' technology platform can greatly assist the company in deeply understanding the underlying logic of diseases, populations, targets, and drugs, accelerate the discovery of drug targets and diagnostic markers, facilitate the development of complex disease diagnostic models, and enhance the efficiency and success rate of clinical trials for drugs and diagnostic products by precisely stratifying clinical trial populations.

Hwasun Micro can create strong synergy with the company’s business. At the technical level, its infrared fluorescence technology, as a fundamental platform technology, has advantages such as a high signal-to-noise ratio and excellent sensitivity, which can significantly enhance the performance of the company's immunoassay and molecular diagnostics products. On the commercial side, Hwasun Micro already has several approved immunofluorescence instruments and reagents, which are being sold in China and overseas regions that recognize Chinese regulatory approvals. Its equipment is characterized by miniaturization and low cost, and most of its testing reagents are related to chronic disease management, aligning closely with the company’s strategic focus on consumer healthcare and primary healthcare. Additionally, it complements the company’s existing infectious disease testing products effectively.